RegulatoryOfficial

Health Canada warns on unauthorised peptides after bacteria found in vials seized in Ottawa

🇨🇦 Health Canada · Thu 12 Nov 2026

Lab tests found Sphingomonas bacteria in an injectable peptide seized from Sage & Summit Wellness Co., and the regulator lists ten unauthorised injectable and oral products.

Health Canada has issued a public advisory telling consumers not to inject or consume unauthorised peptide products. Laboratory testing found the bacteria Sphingomonas aquatilis/melonis in an injectable peptide product seized from Sage & Summit Wellness Co. at 451 Preston Street, Ottawa. The advisory is dated 12 November 2026 (reference RA-82944).

The seizure followed a consumer complaint that the shop was selling unauthorised peptides in-store and on its website. Distribution is described as online and within Ontario. According to the regulator, the company has agreed to stop selling these products as a result of its compliance and enforcement actions.

The affected injectables are labelled BPC-157, hCG, Healing Blend (BPC-157, TB-500), KLOW (BPC-157, TB-500, GHK-Cu, KPV), MOTS-C, SELANK, SEMAX, MELANOTAN-1, Retatrutide and Tesamorelin. One oral product, PURE BPC-157 capsules, is also covered. Some seized vials carried the wording "For Research Purposes Only", which Health Canada says means they were made for laboratory use, not for people, and that such labelling does not make a product legal or exempt it from regulatory requirements.

Health Canada says injecting contaminated products can cause serious infections, hospitalisation and, in severe cases, life-threatening sepsis, with higher risk for people with weakened immune systems. People who have injected a product and develop redness, swelling, pain at the injection site, fever or chills should seek immediate medical attention. The regulator adds that it will keep seizing unauthorised peptides, disrupt distribution channels and work with the Canada Border Services Agency to stop shipments entering the country.

What it means for your team

  • Regulatory teams should note Health Canada's stance that "research use only" labelling gives no exemption from drug requirements, and that injectable peptides are generally regulated as prescription drugs in Canada.
  • Pharmacovigilance and quality staff may see adverse event reports linked to unauthorised peptides; the advisory asks that side effects and complaints be reported to Health Canada.
  • Pharmacies may be asked about safe disposal, as the advisory points consumers to local pharmacies or municipal hazardous-waste guidance.
  • Enforcement is expected to continue, including border cooperation, so online sales channels for peptides remain a priority area for the regulator.

Official source: Health Canada ↗

Article written by VigiEye from the official source (Health Canada). AI-assisted; check the source before acting.

More Regulatory All →